Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pharmacol Res. 2013 Sep;75:3-14. doi: 10.1016/j.phrs.2013.03.006. Epub 2013 Mar 25.

microRNAs as pharmacological targets in cancer.

Author information

  • 1Laboratory of Translational Research in Childhood Cancer, Vall d'Hebron Institut de Recerca, Universitat Autónoma de Barcelona, Spain.

Abstract

The survival rate of cancer patients has increased considerably in the last 20 years owing to significant efforts made in prevention, early detection protocols, combined chemotherapy regimens, targeted therapies, refined radiotherapy and cancer vaccines. However, metastasis and acquired resistance to current therapies represent two major challenges for achieving long-term cure. Therefore, new treatment strategies must be developed. One promising alternative is epigenetic-based therapies, of which miRNAs are at the forefront. MicroRNAs are endogenous small non-coding RNAs, often deregulated in cancer, which regulate gene expression by specific binding to the 3'-UTR of target genes. They are excellent candidates for therapy since miRNAs can regulate multiple targets of the same or different pathways, thereby minimizing the risk of resistance development or compensatory mechanisms. In this review, the mechanisms that lead to miRNA deregulation in cancer, their feasibility as therapeutic tools and the different strategies for the pharmacological manipulation of miRNAs in preclinical animal models are discussed.

Copyright © 2013 Elsevier Ltd. All rights reserved.

KEYWORDS:

Antimirs; Cancer therapy; miRNA mimetics; microRNA

PMID:
23537752
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk